NCT06907043 - A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Advanced Solid Tumors

Interventions

DRUG

EIK1004-001 (IMP1707-001)

PARP1 selective inhibitor

Trial Locations (10)

RECRUITING

PASO Medical, Frankston

RECRUITING

NEXT Virginia, Fairfax

RECRUITING

Florida Cancer Center, Lake Mary

RECRUITING

MD Anderson, Houston

RECRUITING

NEXT Oncology, San Antonio

RECRUITING

Sarah Cannon Research Institute at HealthOne, Denver

RECRUITING

Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital), Jinan

RECRUITING

Chongqing University Cancer Hospital, Chongqing

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai